Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.80 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | PGR | P06401 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PRKCB | P05771 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354177 | 0.89 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL7723356 | 0.89 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL5818558 | 0.89 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL639225 | 0.89 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL5354173 | 0.89 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL23851086 | 0.89 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| Phenol SCHEMBL10796309 | 0.88 | ESR1 (0.96) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL8662653 | 0.88 | ESR1 (0.70) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| SCHEMBL8458725 | 0.88 | ESR1 (0.65) | ESR1ESR2CYP19A1PTGS2CYP3A4 | |
| Phenol SCHEMBL7723405 | 0.88 | ESR1 (0.96) | ESR1ESR2CYP19A1PTGS2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240006654-A1 | LITHIUM-ION CELL WITH A HIGH SPECIFIC ENERGY DENSITY | VARTA MICROBATTERY GMBH (DE) | 2024-01-04 | — | — | US | claimed |
| WO-2022058342-A1 | LITHIUM-ION CELL WITH A HIGH SPECIFIC ENERGY DENSITY | VARTA MICROBATTERY GMBH (DE) | 2022-03-24 | — | — | WO | claimed |
| CN-112279966-B | Styrene derivative copolymer containing diphenylethyl and preparation method of graft polymer thereof | 大连理工大学 | 2021-09-24 | — | — | CN | claimed |
| CN-112279966-A | Styrene derivative copolymer containing diphenylethyl and preparation method of graft polymer thereof | 大连理工大学 | 2021-01-29 | — | — | CN | claimed |
| EP-1786408-A1 | USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT OR PREVENTION OF ANDROGEN DEFICIENCY | Hormos Medical Ltd. (FI) | 2007-05-23 | — | — | EP | claimed |
| US-20060293294-A1 | Method for treatment or prevention of androgen deficiency | HORMOS MEDICAL CORPORATION (FI) | 2006-12-28 | — | — | US | claimed |
| WO-2006084937-A1 | METHOD FOR DIAGNOSING AND TREATING WOMEN WITH INCREASED RESPONSE TO HORMONAL REPLACEMENT THERAPY | LESKELAE HANNU-VILLE (FI) | 2006-08-17 | — | — | WO | claimed |
| WO-2006024689-A1 | USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR USE IN A METHOD FOR THE TREATMENT OR PREVENTION OF ANDROGEN DEFICIENCY | HORMOS MEDICAL LTD. (FI) | 2006-03-09 | — | — | WO | claimed |
| US-5650425-A | ANTICARCINOGENIC, ANTAGONIST, ANTITUMOR AGENTS AND ANTIINFLAMMATORY AGENTS | PHARMOS CORPORATION (US) | 1997-07-22 | — | — | US | claimed |
| EP-0313799-B1 | PROCESS FOR THE PREPARATION OF TRANS-1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES | Klinge Pharma GmbH (DE) | 1993-02-10 | — | — | EP | claimed |
| US-4960937-A | Process for the preparation of trans-1,1,2-triphenyl-but-1-ene derivatives | KLINGE PHARMA GMBH (DE) | 1990-10-02 | — | — | US | claimed |
| EP-0313799-A2 | Process for the preparation of trans-1,1,2-triphenyl-but-1-ene derivatives | Klinge Pharma GmbH (DE) | 1989-05-03 | — | — | EP | claimed |
| EP-0221368-A2 | Substituted 1,1,2-triphenyl-1-butene | ASTA Pharma Aktiengesellschaft (DE) | 1987-05-13 | — | — | EP | claimed |
| EP-0107208-B1 | 1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | Klinge Pharma GmbH (DE) | 1986-01-22 | — | — | EP | claimed |
| EP-0054168-B1 | 1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | Klinge Pharma GmbH (DE) | 1984-07-11 | — | — | EP | claimed |
| JP-7304661-A | — | — | None | — | — | JP | disclosed |
| JP-9315961-A | — | — | None | — | — | JP | disclosed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| US-4198435-A | Pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293294-A1 | Method for treatment or prevention of androgen deficiency | SHBG, NR5A1, AR | ESR1 39/4885ESR2 33/4885CYP19A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.